AQR Capital Management
KRYS icon

AQR Capital Management’s Krystal Biotech KRYS Stock Holding History

AQR Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.2M Sell
14,002
-112
-0.8% -$33.5K ﹤0.01% 1975
2026
Q1 		$3.65M Sell
14,114
-43
-0.3% -$11.4K ﹤0.01% 1945
2025
Q4 		$3.49M Sell
14,157
-5,976
-30% -$1.26M ﹤0.01% 1788
2025
Q3 		$3.55M Buy
20,133
+8,165
+68% +$1.22M ﹤0.01% 1652
2025
Q2 		$1.65M Sell
11,968
-163
-1% -$23.9K ﹤0.01% 1904
2025
Q1 		$2.19M Buy
12,131
+2,792
+30% +$470K ﹤0.01% 1563
2024
Q4 		$1.46M Buy
9,339
+989
+12% +$175K ﹤0.01% 1688
2024
Q3 		$1.52M Buy
8,350
+763
+10% +$147K ﹤0.01% 1629
2024
Q2 		$1.39M Buy
7,587
+1,551
+26% +$260K ﹤0.01% 1614
2024
Q1 		$1.07M Buy
6,036
+1,734
+40% +$241K ﹤0.01% 1658
2023
Q4 		$534K Buy
4,302
+288
+7% +$31.9K ﹤0.01% 1852
2023
Q3 		$466K Sell
4,014
-437
-10% -$53.3K ﹤0.01% 1871
2023
Q2 		$523K Buy
4,451
+507
+13% +$51.8K ﹤0.01% 1774
2023
Q1 		$316K Buy
3,944
+236
+6% +$18.5K ﹤0.01% 1928
2022
Q4 		$294K Buy
+3,708
New +$275K ﹤0.01% 1978
2020
Q3 		– Sell
-8,377
Closed -$347K – 2231
2020
Q2 		$347K Sell
8,377
-3,920
-32% -$189K ﹤0.01% 1855
2020
Q1 		$532K Buy
12,297
+2,448
+25% +$128K ﹤0.01% 1565
2019
Q4 		$545K Sell
9,849
-681
-6% -$33.4K ﹤0.01% 1727
2019
Q3 		$366K Buy
10,530
+1,458
+16% +$65.2K ﹤0.01% 1858
2019
Q2 		$365K Buy
+9,072
New +$297K ﹤0.01% 1817

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AQR Capital Management's KRYS Position: Q2 2026 in Review

AQR Capital Management reduced its Krystal Biotech (KRYS) stake by 0.79% in Q2 2026, selling an estimated $33.5K and leaving 14,002 shares worth $5.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

AQR Capital Management first reported a position in KRYS in Q2 2019 and has held it in 20 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • AQR Capital Management held 14,002 shares of Krystal Biotech worth $5.2M as of Q2 2026.
  • AQR Capital Management sold 112 Krystal Biotech shares in Q2 2026, an estimated $33.5K.
  • Krystal Biotech made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1975 holding.
  • AQR Capital Management first reported a position in Krystal Biotech in Q2 2019 and has held it in 20 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.